GLP-3 R Retatrutide 10mg — Triple Receptor Agonist Peptide
Retatrutide 10mg — The World's Most Potent Metabolic Peptide Now Available for Research
Retatrutide is a first-in-class triple agonist peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. Phase 2 clinical trials documented a staggering 24.2% body weight reduction — surpassing every other anti-obesity agent ever tested — making it the most potent metabolic compound in existence for lab use investigation.
Secure checkout · Third-party tested · Affiliate link
Retatrutide 10mg — The World's Most Potent Metabolic Peptide Now Available for Research
GLP-3 R (Retatrutide) represents the cutting edge of metabolic peptide science. Building on the dual agonist advances of tirzepatide, retatrutide adds glucagon receptor agonism — a critical addition that dramatically amplifies energy expenditure. While GLP-1 receptor activity suppresses appetite and GIP receptor activity improves insulin sensitivity, glucagon receptor activation increases basal metabolic rate by stimulating hepatic glucose production mobilization, thermogenesis in brown adipose tissue, and fatty acid oxidation. The Phase 2 trial published in NEJM (2023) reported 24.2% weight loss at 12mg over 48 weeks — the highest ever documented for a once-weekly treatment.
Retatrutide 10mg Documented Benefits: 6 Documented Mechanisms
Unprecedented Weight Loss Magnitude
Phase 2 trials document 24.2% mean body weight reduction at 12mg — exceeding semaglutide, tirzepatide, and every other anti-obesity agent in head-to-head science comparison. The new benchmark in fat loss science.
Triple Receptor Metabolic Synergy
GLP-1R + GIP-R + GCGR simultaneous activation creates a metabolic environment with combined appetite suppression, insulin sensitization, AND active thermogenesis — three independent pathways driving fat loss simultaneously.
Glucagon-Driven Energy Expenditure
The glucagon receptor component drives increases in basal metabolic rate — a unique feature absent in semaglutide and tirzepatide — allowing energy expenditure to rise even as caloric intake falls.
Liver Fat (MASLD) Reduction
Glucagon receptor agonism powerfully reduces hepatic steatosis — Phase 2 data shows dramatic reductions in liver fat content, with implications for metabolic-associated steatotic liver disease science.
Muscle Mass Preservation
Despite extraordinary fat loss magnitude, retatrutide studies suggest preservation of lean mass at levels comparable to tirzepatide — addressing the central challenge of maintaining muscle during aggressive caloric restriction.
Lipid Profile Optimization
Triple agonism drives comprehensive lipid panel improvements — reductions in triglycerides, LDL, and VLDL alongside HDL improvements — suggesting cardiovascular benefits beyond weight loss magnitude.
How Retatrutide 10mg Works: Molecular Mechanism & Pathway
Retatrutide simultaneously occupies GLP-1R (cAMP/PKA pathway → appetite suppression, insulin secretion), GIP-R (cAMP/PKA pathway → insulin amplification, adipose regulation), and GCGR (cAMP/PKA pathway → hepatic glucose mobilization, thermogenesis, fatty acid oxidation). The C18 lipidated side chain enables albumin binding and a half-life of approximately 6 days. The glucagon component's thermogenic effect through UCP1 activation in brown adipose tissue and ATGL-driven lipolysis in white adipose tissue adds an active metabolic expenditure component that passive appetite suppression cannot achieve.
◈ Key Highlights
- NEJM 2023 Phase 2 trial: 24.2% body weight loss at 12mg — largest ever in a once-weekly treatment RCT
- Liver fat reduction up to 81.7% in MASLD participants in Phase 2 data
- Triglyceride reductions of 42% reported alongside weight loss in Phase 2
- Currently in Phase 3 clinical development — most advanced triple agonist in history
Ideal For
- Cutting-edge triple agonist mechanism science
- Comparative incretin pathway studies
- Thermogenesis and energy expenditure investigation
- Hepatic steatosis science
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
